Aug 29, 2024 / NTS GMT
Steven Gourlay - Actinogen Medical Ltd - Chief Executive Officer, Managing Director
Be here with you again today to explain and elucidate on our further positive depression results from the XanCIDD Phase 2a trial -- Xanamem, and we are going to wait one more second or two for some additional participants and then we will get started.
Okay. I think that looks like it's about it. So the bottom line from today's presentation. And of course, the top line. These results were announced on Monday in an ASX release that we have clinically and statistically significant benefits Xanamem treatment on depression. And importantly, this validates the biologic activity -- 10 milligram dose and really a stent establishes for the first time repeatedly in our view that the code is our hypothesis that inhibiting the stress hormone cortisol in the brain.
Really matters from a clinical point of view and that this approach to therapy of multiple diseases, including depression and Alzheimer's really has traction and really does work. And so to help me explain all of this as our Chief Medical Officer, Dr. Dana, who
Actinogen Medical Ltd Depression Trial Result Webinar Transcript
Aug 29, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers